Wild type ALK

About

Gene context: ALK

Biomarker Type: Wild type

Present: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) CD274 amplification, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab
EMA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
EMA (2) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) Wild type ALK Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pemetrexed, Tislelizumab
EMA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pemetrexed, Tislelizumab